Ken Griffin Essa Pharma Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Essa Pharma Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 4,600 shares of EPIX stock, worth $29,808. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,600

Previous 6,300 26.98%

Holding current value

$29,808

Previous $53,000 54.72%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.63 - $8.42 $52,749 - $95,929	-11,393 Reduced 31.2%	25,125 $132,000
Q1 2024 May 15, 2024	SELL	$6.17 - $10.65 $1.4 Million - $2.42 Million	-227,089 Reduced 86.15%	36,518 $310,000
Q4 2023 Feb 14, 2024	BUY	$2.74 - $7.35 $707,281 - $1.9 Million	258,132 Added 4714.74%	263,607 $1.74 Million
Q3 2023 Nov 14, 2023	SELL	$2.65 - $3.31 $14,331 - $17,900	-5,408 Reduced 49.69%	5,475 $16,000
Q2 2023 Aug 14, 2023	BUY	$2.6 - $3.34 $28,295 - $36,349	10,883 New	10,883 $29,000
Q4 2021 Feb 14, 2022	SELL	$7.8 - $14.38 $1.57 Million - $2.9 Million	-201,634 Reduced 29.41%	483,897 $6.87 Million
Q3 2021 Nov 15, 2021	SELL	$7.76 - $29.37 $272,919 - $1.03 Million	-35,170 Reduced 4.88%	685,531 $5.49 Million
Q2 2021 Aug 16, 2021	BUY	$24.17 - $34.28 $5.66 Million - $8.02 Million	234,042 Added 48.09%	720,701 $20.6 Million
Q1 2021 May 17, 2021	BUY	$11.61 - $32.08 $987,395 - $2.73 Million	85,047 Added 21.18%	486,659 $14.1 Million
Q4 2020 Feb 16, 2021	SELL	$5.47 - $12.1 $4,004 - $8,857	-732 Reduced 0.18%	401,612 $4.79 Million
Q3 2020 Nov 16, 2020	BUY	$6.0 - $7.79 $2.41 Million - $3.13 Million	402,344 New	402,344 $2.78 Million

Others Institutions Holding EPIX

# of Institutions

Shares Held

35.2M

Call Options Held

37.7K

Put Options Held

3.8K

View Full List

About ESSA Pharma Inc.

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $286M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

More about EPIX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account